Peripheral Arterial Disease

LAS VEGAS — In a real-world population with peripheral artery disease, nearly three-quarters of patients treated with a drug-coated balloon were free from clinically driven target lesion revascularization at 4 years, according to new data presented at VIVA 19.

LAS VEGAS — A low-dose paclitaxel-coated balloon was superior to percutaneous transluminal angioplasty for treatment of femoropopliteal disease, according to results from a prespecified interim 1-year analysis from the RANGER II SFA trial presented at VIVA 19.

LAS VEGAS — A peripheral drug-eluting stent with a polymer coating conferred lower rates of target lesion revascularization compared with a peripheral DES without a polymer coating, according to 2-year results from the IMPERIAL trial.

LAS VEGAS — There were no significant differences in mortality at 5 years between patients with peripheral artery disease assigned a drug-eluting stent and those assigned a bare-metal stent or percutaneous transluminal angioplasty, according to new data presented at VIVA 19.

LAS VEGAS — There has never been a randomized trial to determine what interventions may prevent progression from claudication to critical limb ischemia, but current evidence suggests one might be warranted, a speaker said at VIVA 19.

Patients who underwent endovascular revascularization with a paclitaxel-based drug-eluting device did not have an increased mortality risk over an 11-year follow-up period, according to a safety analysis published in the European Heart Journal.

In recognition of Peripheral Artery Disease Awareness Month in September, Healio has compiled a list of five recent updates on PAD.

PARIS — Patients with peripheral artery disease who maintained use of high-intensity statin therapy had significantly lower mortality than those who reduced the intensity of statin treatment or stopped taking statins, researchers reported.

Orchestra BioMed Inc., in partnership with Terumo Corporation, announced its sirolimus-eluting balloon for the treatment of below-the-knee peripheral artery disease, has received breakthrough device designation from the FDA.

Healio compiled a list of the most-read cardiac and vascular intervention articles in August. This month, our readers were interested in the FDA approval of transcatheter aortic valve replacement devices for use in patients at low surgical risk, FDA recommendations on the signal of late mortality risk associated with paclitaxel-coated devices, the benefits of antiplatelet therapy in patients with atrial fibrillation who had TAVR and much more.